- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00213603
Follow-up Modalities of Low Grade Precancerous Bronchial Lesions
Endoscopic Follow-up of Low Grade Precancerous Bronchial Lesions in High Risk Patients (SELEPREBB1)
The goal of this multicentric French randomized trial is to determine the best auto fluorescence bronchial endoscopic follow-up strategy in high risk patients bearing low grade bronchial precancerous lesions. Subjects will be randomly assigned to one of the following arm :
(A) every 6 months clinical and chest Xrays follow-up without intermediate endoscopy, (B) every 6 months clinical and chest Xrays follow-up including repeated autofluorescence endoscopy and biopsies on a 6 months basis in case of low grade dysplasia or on a one year basis in patients without dysplasia.
After 36 months follow-up, each patient from the two groups will be subjected to a final autofluorescence endoscopy and biopsy and a Spiral Chest Xray.
The final analysis will compare between the two groups :
- The probability of progression from an initially identified low grade lesion to a high grade lesion
- The probability of respiratory epithelial tract progression assessed by the occurrence of a lung cancer or high grade lesion.
- The characteristics of lung cancers detected in each arm
- In both arm, the influence of risk factors and persistent exposure to tobacco on lesion evolutivity.
Study Overview
Status
Conditions
Detailed Description
The goal of this multicentric French randomized trial is to determine the best auto fluorescence bronchial endoscopic follow-up strategy in high risk patients bearing low grade bronchial precancerous lesions. This Trial compares two follow-up modalities : observation without endoscopy for a three year period (group A " light " follow-up), versus repeated autofluorescence endoscopies and biopsies every six months for three years (group B " intensive ").
Methods: 300 subjects at high risk for lung cancer will be included over a two year period and followed-up for three years. In each subject an auto-fluorescence endoscopy and a Chest CT scan will be performed before the enrollment into the trial. To be included the subject must present with an initial Chest CT scan not suspicious for lung cancer and bronchial biopsy showing a moderate dysplasia or a lower grade lesion.
Subjects will be randomly assigned to one of the following arm :
(A) every 6 months clinical and chest Xrays follow-up without intermediate endoscopy, (B) every 6 months clinical and chest Xrays follow-up including repeated autofluorescence endoscopy and biopsies on a 6 months basis in case of low grade dysplasia or on a one year basis in patients without dysplasia.
Stratifications factors for randomization are: Center, occupational exposure to respiratory carcinogens, presence of a bronchial low dysplastic lesion versus absence of dysplasia.
Bronchial biopsies samples will be centrally reviewed by a panel of Pathologists.
After 36 months follow-up, each patient from the two groups will be subjected to a final autofluorescence endoscopy and biopsy and a Spiral Chest Xray.
The final analysis will compare between the two groups :
- The probability of progression from an initially identified low grade lesion to a high grade lesion
- The probability of respiratory epithelial tract progression assessed by the occurrence of a lung cancer or high grade lesion.
- The characteristics of lung cancers detected in each arm
- In both arm, the influence of risk factors and persistent exposure to tobacco on lesion evolutivity.
First inclusion into the trial : July 2002, End of recruitment December 2005, End of follow- up : december 2008.
An ancillary study analysing the performances of fibered confocal fluorescence microscopy has been started in december 2005 after IRB/ethical comity approval. This ancillary study is only performed at the Rouen University Hospital Center.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Haute Normandie
-
Rouen, Haute Normandie, France, 76000
- Rouen University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Patient with one or several of the following risk factor for lung cancer:
- Tobacco consumption more than 30 pack years
- Lung or ENT cancer history, cured
- Occupational exposure to respiratory carcinogens
- Normal baseline CT scan
- Autofluorescence endoscopy showing moderate dysplasia or lower grade lesion
- Written informed consent
Exclusion Criteria:
- Treatment with Vit A derivative
- Contra indication for a fiberoptic bronchoscopy under local anesthesia.
- Known evolutive cancer
- Chest radiation therapy within 5 years before inclusion or chemotherapy within two years before inclusion.
- Impossibility for a 3 years follow-up
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
occurence of high grade lesion or occurence of a cancer during endoscopic or clinical follow up
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Luc c Thiberville, MD, Rouen University Hospital
Publications and helpful links
General Publications
- Thiberville L, Moreno-Swirc S, Vercauteren T, Peltier E, Cave C, Bourg Heckly G. In vivo imaging of the bronchial wall microstructure using fibered confocal fluorescence microscopy. Am J Respir Crit Care Med. 2007 Jan 1;175(1):22-31. doi: 10.1164/rccm.200605-684OC. Epub 2006 Oct 5.
- Guisier F, Deslee G, Birembaut P, Escarguel B, Chapel F, Bota S, Metayer J, Lachkar S, Capron F, Homasson JP, Taulelle M, Quintana M, Raspaud C, Messelet D, Benzaquen J, Hofman P, Baddredine J, Paris C, Cales V, Laurent P, Vignaud JM, Menard O, Copin MC, Ramon P, Bouchindhomme B, Tavernier JY, Quintin I, Quiot JJ, Galateau-Salle F, Zalcman G, Piton N, Thiberville L. Endoscopic follow-up of low-grade precancerous bronchial lesions in high-risk patients: long-term results of the SELEPREBB randomised multicentre trial. Eur Respir J. 2022 Sep 15;60(3):2101946. doi: 10.1183/13993003.01946-2021. Print 2022 Sep.
- Salaun M, Roussel F, Bourg-Heckly G, Vever-Bizet C, Dominique S, Genevois A, Jounieaux V, Zalcman G, Bergot E, Vergnon JM, Thiberville L. In vivo probe-based confocal laser endomicroscopy in amiodarone-related pneumonia. Eur Respir J. 2013 Dec;42(6):1646-58. doi: 10.1183/09031936.00191911. Epub 2012 Sep 27.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2001/032/HP
- PHRC French ministry of Health
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thoracic Neoplasms
-
Royal Marsden NHS Foundation TrustMerck Sharp & Dohme LLC; Institute of Cancer Research, United Kingdom; National...Unknown
-
University Medical Center GroningenCompletedThoracic TumorNetherlands
-
Fondation LenvalCompletedNeurogenic Thoracic TumorsFrance
-
Hospices Civils de LyonNot yet recruitingHigh-risk Thoracic Cancer SurgeryFrance
-
University Medical Center GoettingenRecruitingPelvic Tumor | Thoracic TumorGermany
-
Dartmouth-Hitchcock Medical CenterTerminated
-
Ohio State University Comprehensive Cancer CenterNational Comprehensive Cancer NetworkRecruitingMalignant Thoracic NeoplasmUnited States
-
Asan Medical CenterCompletedAbdominal Neoplasm | Thoracic NeoplasmKorea, Republic of
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRecruitingThoracic Cancer | Palliative Care | RadiotherapyItaly